Respiratory Infection (for Example, Pneumonia, Bronchitis)SCORE-PedsNCT07334795
Intermountain Stewardship in Community Outpatient Settings-Resources & Engagement-Pediatrics
An observational study of Respiratory Infection (for Example, Pneumonia, Bronchitis) and Antibiotic, run by Intermountain Health Care, Inc. at 1 site in United States.
Trial summary
The goal of this implementation project is to detail the process of implementing the best practice of antibiotic stewardship in the pediatric population across the Intermountain Health medical system. Read more about this study
- Who is it for?
- Ages 6 months to 17 years
- Conditions the study is for
- Respiratory Infection (for Example, Pneumonia, Bronchitis), Antibiotic, Antibiotic Duration
- What is being tested?
- Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation
- How many people
- 259,000 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jan 2026to 15 Jan 2029
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 17 years
- All sexes
- No healthy volunteers
- Child
Study population: All children meeting eligibility criteria and treated at any facility within the Intermountain region specified (wave 1 \& wave 2) between January 1, 2026 and December 31, 2028.
Who may be able to join
- Age 6 months through 17 years
- ARTI diagnosis (acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP))
Who cannot join
- Age <6months or >18 years
- No ARTI diagnosis
Trial locations and contacts
1 site in 1 country.
About this study
The goal of this implementation project is to detail the process of implementing the best practice of antibiotic stewardship in the pediatric population across the Intermountain Health medical system. The main questions it aims to answer are:
- How can a large healthcare system drive high adherence to antibiotic stewardship across a large and diverse number of sites?
- How do determinants of implementation and needed strategies vary by context?
- What is the utility of a higher-resource implementation effort (named "Boost) focusing on outlier sites?
Data will be collected on number of children reached, adherence changes over time, types of implementation strategies employed, and characteristics of sites, prescribers, and patients.
- Conditions
- Respiratory Infection (for Example, Pneumonia, Bronchitis), Antibiotic, Antibiotic Duration, Antibiotic Prescribing for Acute Respiratory-tract Infections
- Being tested
- Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation
- Medical subject headings
- Respiratory Tract Infections, Pneumonia, Bronchitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitationOther
- facilitate improved adherence to guideline-based prescribing, we plan a variety of implementation strategies to be employed in tandem including training \& education, EMR tools (e.g., Smart sets, express lanes, preference lists), audit and feedback reports and dashboards, and facilitation.
| Study group | Role | What they receive |
|---|---|---|
| Children with ARTIs, Wave 1 | Children under 18 treated in Wave 1 of antibiotic stewardship for the following conditions: acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP) Receives: Other: Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation | |
| Children with ARTIs, Wave 2 | Children under 18 treated in Wave 2 of antibiotic stewardship for the following conditions: acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP) Receives: Other: Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Guideline-adherent Broad vs. Narrow Spectrum Antibiotic Prescribing
Rates of narrow-spectrum antibiotic (AB) prescriptions as a proportion of all antibiotics prescribed in aggregate and within each of these diagnoses: Acute otitis media, Group A streptococcal pharyngitis, Acute sinusitis, and Pneumonia.
Measured: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Guideline-adherent Duration of Antimicrobial Therapy
Rate of AB prescriptions with guideline-adherent number of days prescribed as proportion of all AB prescriptions in aggregate and for each of the target ARTI diagnoses.
Measured: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Secondary outcomes (3)
Rate of Treatment Failure
Clinical encounter for the same diagnosis between 2 and 14 days following the index encounter and receipt of an alternative antibiotic for the same respiratory diagnosis during the return visit.
Measured: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation
Adoption (Staff): Adherence to Protocols
Number and proportion of prescribers who are "adherent" to guideline-based prescribing protocols for Broad vs. Narrow Spectrum AB Prescribing, and Duration.
Measured: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation
Adoption (Organization): Adherence to Protocols
Number and proportion of sites where 60% of prescribers are adherent.
Measured: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start15 Jan 2026
- Primary completion15 Jan 2029 (estimated)
- Study completion15 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Respiratory Infection (for Example, Pneumonia, Bronchitis)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 259,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Intermountain Health Care, Inc.
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07334795
- Sponsor's protocol ID
- HSII_IHC_IMP-PS2
- Acronym
- SCORE-Peds
- Status last verified
- Oct 2025
- First submitted
- 31 Dec 2025
- Last updated
- 27 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This is an implementation study using observational data with a waiver of consent. Therefore, there is no consent to allow for the sharing of IPD.
Publications
Fowles TR, Patel PK, Seibert AM, Hersh AL, Belnap T, Hanna B, Szymczak JE, Keenan HT, Barney BJ, Srivastava R. Implementation of a pediatric antibiotic stewardship intervention across a large integrated health system: protocol to optimize antibiotic selection and prescription duration for acute respiratory tract infections in children. Implement Sci Commun. 2026 Apr 9;7(1):93. doi: 10.1186/s43058-026-00915-0.
PubMed 41952161